Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.48 |
| ▸ | FLT3 | P36888 | 5/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | CSF1R | P07333 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | KIT | P10721 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | FRK | P42685 | 3/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.45 |
| ▸ | AXL | P30530 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.45 |
| ▸ | FLT4 | P35916 | 3/20 | 0.45 |
| ▸ | BLK | P51451 | 3/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58416 | 0.93 | KDR (0.51) | FLT3KDRCSF1RFLT1KIT | |
| SCHEMBL60045 | 0.92 | FLT3 (0.47) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL58420 | 0.88 | FLT3 (0.54) | FLT3KDRCSF1RFLT1KIT | |
| SCHEMBL59668 | 0.87 | FLT3 (0.58) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL59369 | 0.87 | FLT3 (0.49) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL58142 | 0.85 | ACVRL1 (0.57) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL59275 | 0.84 | FLT3 (0.51) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL58929 | 0.83 | FLT3 (0.48) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL59832 | 0.82 | ACVRL1 (0.50) | ERN1FLT3KDRCSF1RFLT1 | |
| SCHEMBL58187 | 0.81 | ACVRL1 (0.46) | ERN1FLT3KDRCSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ERN1 4551/4885FLT3 299/4885KDR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.